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Abstract 
Background/Aims: Recent evidence suggests that hepatocellular carcinoma can be 
classified into certain molecular subtypes with distinct prognoses based on the 
stem/maturational status of the tumor. We investigated the transcription program 
deregulated in hepatocellular carcinomas with stem cell features.  
Methods: Gene and protein expression profiles were obtained from 238 (analyzed by 
microarray), 144 (analyzed by immunohistochemistry), and 61 (analyzed by qRT-PCR) 
hepatocellular carcinoma cases. Activation/suppression of an identified transcription 
factor was used to evaluate its role in cell lines. The relationship of the transcription 
factor and prognosis was statistically examined.  
Results: The transcription factor SALL4, known to regulate stemness in embryonic and 
hematopoietic stem cells, was found to be activated in a hepatocellular carcinoma 
subtype with stem cell features. SALL4-positive hepatocellular carcinoma patients were 
associated with high values of serum alpha fetoprotein, high frequency of hepatitis B 
virus infection, and poor prognosis after surgery compared with SALL4-negative 
patients. Activation of SALL4 enhanced spheroid formation and invasion capacities, 
key characteristics of cancer stem cells, and up-regulated the hepatic stem cell markers 
KRT19, EPCAM, and CD44 in cell lines. Knockdown of SALL4 resulted in the 
down-regulation of these stem cell markers, together with attenuation of the invasion 
capacity. The SALL4 expression status was associated with histone deacetylase activity 
in cell lines, and the histone deacetylase inhibitor successfully suppressed proliferation 
of SALL4-positive hepatocellular carcinoma cells.  
Conclusions: SALL4 is a valuable biomarker and therapeutic target for the diagnosis 
and treatment of hepatocellular carcinoma with stem cell features.  
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Introduction 
Cancer is a heterogeneous disease in terms of morphology and clinical behavior. This 
heterogeneity has traditionally been explained by the clonal evolution of cancer cells 
and the accumulation of serial stochastic genetic/epigenetic changes [1]. The alteration 
of the microenvironment by tumor stromal cells is also considered to contribute to the 
development of the heterogeneous nature of the tumor through the activation of various 
signaling pathways in cancer cells, including epithelial mesenchymal transition 
programs [2].  
Recent evidence suggests that a subset of tumor cells with stem cell features, 
known as cancer stem cells (CSCs), are capable of self-renewal and can give rise to 
relatively differentiated cells, thereby forming heterogeneous tumor cell populations [3]. 
CSCs were also found to generate tumors more efficiently in immunodeficient mice 
than non-cancer stem cells in various solid tumors as well as hematological 
malignancies [4]. CSCs are also more metastatic and chemo/radiation-resistant than 
non-CSCs and are therefore considered to be a pivotal target for tumor eradication [5, 
6]. 
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide 
[7]. Recently, we proposed a novel HCC classification system based on the expression 
status of the hepatic stem/progenitor markers epithelial cell adhesion molecule 
(EpCAM) and alpha fetoprotein (AFP) [8]. EpCAM-positive (+) AFP+ HCC (hepatic 
stem cell-like HCC; HpSC-HCC) is characterized by an onset of disease at younger 
ages, activation of Wnt/β-catenin signaling, a high frequency of portal vein invasion and 
poor prognosis after radical resection, compared with EpCAM- AFP- HCC (mature 
hepatocyte-like HCC; MH-HCC) [9]. EPCAM is a target gene of Wnt/β-catenin 
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signaling, and EpCAM+ HCC cells isolated from primary HCC and cell lines show CSC 
features including tumorigenicity, invasiveness, and resistance to fluorouracil [9, 10]. 
Thus, EpCAM appears to be a potentially useful marker for the isolation of liver CSCs 
in HpSC-HCC. However, key transcriptional programs responsible for the maintenance 
of EpCAM+ CSCs are still unclear. 
 In this study, we aimed to clarify the transcriptional programs deregulated in 
HpSC-HCC using a gene expression profiling approach. We found that the SALL4 gene 
encoding Sal-like 4 (Drosophila) (SALL4), a zinc finger transcriptional activator and 
vertebrate orthologue of the Drosophila gene spalt (sal) [11], was up-regulated in 
HpSC-HCC. In adults, SALL4 is known to be expressed in hematopoietic stem cells 
and their malignancies, but its role in HCC has not yet been fully elucidated [12-14]. 
We therefore investigated the role of SALL4 in the regulation and maintenance of 
EpCAM+ HCC. 
 
Materials and methods 
Clinical HCC specimens 
A total of 144 HCC tissues and adjacent non-cancerous liver tissues were obtained from 
patients who underwent hepatectomy for HCC treatment from 2002 to 2010 at 
Kanazawa University Hospital, Kanazawa, Japan. These samples were formalin-fixed 
and paraffin-embedded, and used for immunohistochemistry (IHC). A further 61 HCC 
samples were obtained from patients who underwent hepatectomy from 2008 to 2011; 
these were freshly snap-frozen in liquid nitrogen and used for RNA analysis. Of these 
61 HCCs, eight and 36 cases were defined as HpSC-HCC and MH-HCC, respectively, 
according to previously described criteria [8].  
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Twenty-seven HCC cases were included in both the IHC cohort (n =144) and 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR) cohort (n = 61), 
and SALL4 gene and protein expression were compared between these cases. An 
additional fresh HpSC-HCC sample was obtained from a surgically resected specimen 
and immediately used for preparation of a single-cell suspension. All experimental and 
tissue acquisition procedures were approved by the Ethics Committee and the 
Institutional Review Board of Kanazawa University Hospital. All patients provided 
written informed consent. 
Microarray analysis 
Detailed information on microarray analysis is available in the supplemental text.  
Cell culture and reagents 
Human liver cancer cell lines HuH1, HuH7, HLE, and HLF were obtained from the 
Japanese Collection of Research Bioresources (JCRB), and Hep3B and SK-Hep-1 were 
obtained from the American Type Culture Collection (ATCC). Single-cell suspensions 
of a primary HCC tissue were prepared as described previously [15]. Detailed 
information is available in the supplemental text. The histone deacetylase (HDAC) 
inhibitor suberic bis-hydroxamic acid (SBHA) and suberoylanilide hydroxamic acid 
(SAHA) were obtained from Cayman Chemical (Ann Arbor, MI). Plasmid constructs 
pCMV6-SALL4 (encoding SALL4A), pCMV6-SALL4-GFP, and 29mer shRNA 
constructs against human SALL4 (No. 7412) were obtained from OriGene Technologies, 
Inc. (Rockville, MD). These constructs were transfected using Lipofectamine 2000 
(Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. 
Western blotting 
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Whole cell lysates were prepared using RIPA lysis buffer. Nuclear and cytoplasmic 
proteins were extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Pierce Biotechnology Inc., Rockford, IL). Mouse monoclonal antibody to human Sall4 
clone 6E3 (Abnova, Walnut, CA), rabbit polyclonal antibodies to human Lamin B1 
(Cell Signaling Technology Inc., Danvers, MA), and mouse monoclonal anti-β-actin 
antibody (Sigma-Aldrich, St. Louis, MO) were used. Immune complexes were 
visualized by enhanced chemiluminescence (Amersham Biosciences Corp., Piscataway, 
NJ) as described previously [15, 16]. 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
Detailed information on qRT-PCR is available in the supplemental text. 
IHC and immunofluorescence (IF) analyses  
IHC was performed using an Envision+ kit (Dako, Carpinteria, CA) according to the 
manufacturer’s instructions. Anti-SALL4 monoclonal antibody 6E3 (Abnova, Walnut, 
CA), anti-EpCAM monoclonal antibody VU-1D9 (Oncogene Research Products, San 
Diego, CA), and anti-CK19 monoclonal antibody RCK108 (Dako Japan, Tokyo, Japan) 
were used for detecting SALL4, EpCAM, and CK19, respectively. Anti-Sall4 rabbit 
polyclonal antibodies (ab29112) (Abnova) and vector red (Vector Laboratories Inc., 
Burlingame, CA) were used for double color IHC analysis. Samples with >5% positive 
staining in a given area were considered to be positive for a particular antibody. For IF 
analyses, Alexa 488 fluorescein isothiocyanate (FITC)-conjugated anti-mouse 
immunoglobulin G (IgG) (Life Technologies) was used as a secondary antibody. 
Cell proliferation, spheroid formation, invasion, and HDAC activity assay 
Detailed information on this topic is available in the supplemental text.  
Statistical analyses 
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Student t-tests were performed with GraphPad Prism software 5.0 (GraphPad Software, 
San Diego, CA) to compare various test groups assayed by cell proliferation assays and 
qRT-PCR analysis. Spearman’s correlation analysis and Kaplan-Meier survival analysis 




Activation of SALL4 in HpSC-HCC. To elucidate the transcriptional 
programs deregulated in HpSC-HCC, we performed class-comparison analyses and 
identified 793 genes showing significant differences in differential expression between 
HpSC-HCC (n = 60) and MH-HCC (n = 96) (P < 0.001), as previously described [9]. 
Of them, 455 genes were specifically up-regulated in HpSC-HCC, and we performed 
transcription factor analysis using this gene set to identify their transcriptional 
regulators by MetaCore software. We identified four transcription factor genes, SALL4, 
NFYA, TP53, and SP1, that were potentially activated in HpSC-HCC (Fig. 1A). 
Involvement of TP53 and SP1 in the stemness of HCC has previously been described 
[17, 18], but the roles of SALL4 and NFYA were unclear.  
We investigated the interaction networks affected by SALL4 and NFYA using 
the MetaCore dataset. We showed that SALL4 might be a regulator of Akt signaling 
(SP1), Wnt signaling (TCF7L2), and epigenetic modification (JARID2, DMRT1, 
DNMT3B) [19], and could potentially regulate two other transcriptional regulators, SP1 
and NFYA, through Akt and Myb signaling pathways (Fig. 1B). As a recent study 
indicated that SALL4 is a direct target of the Wnt signaling pathway [20], which is 
dominantly activated in HpSC-HCC [9], we focused on the expression of SALL4 in 
HpSC-HCC, and confirmed its up-regulation in HpSC-HCC compared with MH-HCC 
as evaluated by microarray data (Fig. 1C). We validated this using an independent HCC 
cohort evaluated by qRT-PCR (Fig. 1D). We further examined the expression of SALL4, 
EPCAM, and AFP using microarray data of 238 HCC cases (Fig. 1E) and qRT-PCR 
data of 61 HCC cases (Fig. 1F). For the tumor/non-tumor ratios, we identified a weak 
positive correlation between SALL4 and EPCAM (r = 0.31, P < 0.0001) and between 
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SALL4 and AFP (r = 0.31, P = 0.0003) in the microarray cohort. We further evaluated 
expression of these genes in HCC tissues by qRT-PCR, and we validated the strong 
positive correlation between SALL4 and EPCAM (r = 0.70, P < 0.0001) and between 
SALL4 and AFP (r = 0.66, P < 0.0001) in the independent cohort. 
Next we performed IHC analysis of 144 HCC cases surgically resected at 
Kanazawa University Hospital. We first confirmed the nuclear accumulation of SALL4 
stained by an anti-human SALL4 antibody (Fig. 2A). We further confirmed the 
concordance of SALL4 protein expression evaluated by IHC, and SALL4 gene 
expression evaluated by qRT-PCR using the same samples (Fig. 2B). We detected the 
nuclear expression of SALL4 in 43 of 144 HCC cases (Table 1). After evaluating the 
clinicopathological characteristics of SALL4-positive and -negative HCC cases, we 
identified that SALL4-positive HCCs were associated with a significantly high 
frequency of hepatitis B virus (HBV) infection and significantly high serum AFP values. 
We further identified that SALL4-positive HCCs were associated with expression of the 
hepatic stem cell markers EpCAM and CK19. Co-expression of SALL4, EpCAM, and 
CK19 was confirmed by double color IHC analysis (Fig. 2C). Evaluation of the survival 
outcome of these surgically resected HCC cases by Kaplan-Meier survival analysis 
indicated that SALL4-positive HCCs were associated with significantly lower 
recurrence-free survival outcomes within one year compared with SALL4-negative 
HCCs (P = 0.0049) (Fig. 2D). 
Because SALL4 expression was positively correlated with EpCAM and AFP 
expression in primary HCC cases, we evaluated the expression of SALL4 in EpCAM+ 
AFP+ and EpCAM- AFP- HCC cell lines. Consistent with the primary HCC data, two of 
three EpCAM+ AFP+ HCC cell lines (Hep3B and HuH7) abundantly expressed SALL4, 
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as shown by qRT-PCR (Fig. 2E) and Western blotting (Fig. 2F). We identified the 
expression of two isoforms of SALL4 proteins with molecular weights of 165 kD 
(SALL4A) and 115 kD (SALL4B), and SALL4B was found to be the dominant 
endogenous isoform in HCC cell lines. All EpCAM- AFP- HCC cell lines (SK-Hep-1, 
HLE, and HLF) and one EpCAM+ AFP+ cell line (HuH1) did not express SALL4. 
Nuclear accumulation of SALL4 in Hep3B and HuH7 cells was confirmed by IHC 
using subcutaneous tumors developed in xenotransplanted NOD/SCID mice (Fig. 2G). 
We further evaluated the expression of EPCAM and SALL4 using single cell 
suspensions derived from a surgically resected primary HCC. EpCAM+ and EpCAM- 
cells were separated by magnetic beads, and we revealed a strong spheroid formation 
capacity of sorted EpCAM+ cells compared with EpCAM- cells (Fig. 2H, left panel). 
Interestingly, when comparing the expression of SALL4 in these sorted cells, we 
identified a high expression of SALL4 in sorted EpCAM+ cells compared with EpCAM- 
cells (Fig. 2H, right panel), indicating that SALL4 is activated in EpCAM+ liver CSCs.  
SALL4 regulates stemness of HpSC-HCC. To explore the role of SALL4 in 
HpSC-HCC, we evaluated the effect of its overexpression in HuH1 cells which showed 
little expression of SALL4 irrespective of EpCAM+ and AFP+ HpSC-HCC phenotype. 
We transfected plasmid constructs encoding SALL4 (pCMV6-SALL4) or control 
(pCMV7), and we similarly identified the expression of two isoforms by using this 
construct (Fig. 3A). Evaluation of the subcellular localization of GFP-tagged SALL4 
(pCMV6-SALL4-GFP) showed that it could be detected in both the cytoplasm and 
nucleus (Fig. 3B). We observed strong up-regulation of the hepatic stem cell marker 
KRT19, modest up-regulation of EPCAM and CD44, and down-regulation of the mature 
hepatocyte marker ALB in HuH1 cells transfected with pCMV6-SALL4 compared with 
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control (Fig. 3C). Up-regulation of CK19 by SALL4 overexpression was also confirmed 
at the protein level by IF analysis (Fig. 3D). Phenotypically, SALL4 overexpression in 
HuH1 cells resulted in the significant activation of spheroid formation and invasion 
capacities with activation of SNAI1, which induces epithelial-mesenchymal transition, 
compared with the control (Fig. 3E & 3F, Supplemental Fig. 1A).  
 We further investigated the effect of SALL4 knockdown in HuH7 cells which 
intrinsically expressed high levels of SALL4. Expression of SALL4 was decreased to 
50% in HuH7 cells transfected with SALL4 sh-RNA compared with control when 
evaluated by qRT-PCR (Fig.4A). However, the reduction of SALL4 protein was more 
evident when evaluated by Western blotting, suggesting that this sh-RNA construct 
might work at the translational as well as the transcriptional level (Fig. 4B). Knock 
down of SALL4 resulted in a compromised invasion capacity and spheroid formation 
capacity with decreased expression of EPCAM and CD44 in HuH7 cells (Fig. 4C & 4D, 
Supplemental Fig. 1B and 1C).  
SALL4 and HDAC activity in HpSC-HCC. The above data suggested that 
SALL4 is a good target and biomarker for the diagnosis and treatment of HpSC-HCCs. 
However, it is difficult to directly target SALL4 as no studies have investigated the 
inhibition of its transcription using chemical or other approaches [21]. We therefore 
re-investigated the interaction networks associated with SALL4, and found that SALL4 
activation appeared to induce epigenetic modification (Fig. 1B). In particular, a recent 
study suggested that SALL4 forms a nucleosome remodeling and deacetylase (NuRD) 
complex with HDACs and potentially regulates HDAC activity [22]. We therefore 
confirmed that SALL4 knock down resulted in the reduced activity of total HDAC in 
HuH7 cells (Fig. 4E). We also evaluated the effect of the overexpression of SALL4 in 
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HuH1 and HLE cells, which do not express SALL4 endogenously, and SALL4 
overexpression was found to result in a modest increase of HDAC activity and mild 
enhancement of chemosensitivity to an HDAC inhibitor SBHA in both cell lines 
(Supplemental Fig. 2A and 2B). We further investigated HDAC activity in two 
SALL4-positive (Hep3B, HuH7) and two SALL4-negative (HLE, HLF) HCC cell lines. 
Interestingly, high HDAC activities were detected in SALL4-positive compared with 
SALL4-negative HCC cell lines (Fig. 4F). The HDAC inhibitor SBHA was found to 
inhibit proliferation of SALL4-positive HCC cell lines at 10 µM concentration. By 
contrast, SBHA had little effect on the proliferation of SALL4-negative HCC cell lines 
at this concentration (Fig. 4G). SBHA treatment suppressed the expression of SALL4 
gene/protein expression in SALL4-positive HuH7 and Hep3B cell lines (Supplemental 
Fig. 3A and 3B). We further investigated the effect of SAHA, an additional HDAC 
inhibitor, in these HCC cell lines, and SAHA was found to more efficiently suppress the 
cell proliferation of SALL4-positive cell lines compared with SALL4-negative cell lines 
(Supplemental Fig. 3C). 
Taken together, our data suggest a pivotal role for the transcription factor 
SALL4 in regulating the stemness of HpSC-HCC. SALL4 was detected in HpSC-HCCs 
with poor prognosis, and inactivation of SALL4 resulted in a reduced invasion/spheroid 
formation capacity and decreased expression of hepatic stem cell markers. The HDAC 
inhibitors inhibited proliferation of SALL4-positive HCC cell lines with a reduction of 





Stemness traits in cancer cells are currently of great interest because they may explain 
the clinical outcome of patients according to the malignant nature of their tumor. 
Recently, we proposed an HCC classification system based on the stem/maturation 
status of the tumor by EpCAM and AFP expression status [8]. These HCC subtypes 
showed distinct gene expression patterns with features resembling particular stages of 
liver lineages. Among them, HpSC-HCC was characterized by a highly invasive nature, 
chemoresistance to fluorouracil, and poor prognosis after radical resection, warranting 
the development of a novel therapeutic approach against this HCC subtype [9].  
In this study, we showed that the transcription factor SALL4 was activated in 
HpSC-HCC and that SALL4 might regulate HCC stemness, as characterized by the 
activation of EpCAM, CK19, and CD44 with highly tumorigenic and invasive natures. 
Furthermore, we identified that SALL4-positive HCC cell lines tended to show high 
HDAC activity and chemosensitivity to the HDAC inhibitors SBHA and SAHA. This 
study reveals for the first time the utility of SBHA for the treatment of HCC with stem 
cell features. 
 SALL4 is a zinc finger transcription factor originally cloned based on sequence 
homology to Drosophila sal [11]. SALL4 mutations are associated with Okihiro 
syndrome, a human disease involving multiple organ defects [23, 24]. SALL4 plays a 
fundamental role in the maintenance of embryonic stem cells, potentially through 
interaction with Oct4, Sox2, and Nanog [25-30]. Furthermore, knockdown of SALL4 
significantly reduces the efficiency of induced pluripotent stem cell generation [31]. 
SALL4 is also expressed in hematopoietic stem cells and leukemia cells, where it 
regulates their maintenance [14, 32]. SALL4 is known to encode two isoforms 
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(SALL4A and SALL4B), and a recent study suggested the important role of SALL4B 
on maintaining the stemness of embryonic stem cells [25]. Interestingly, our data 
indicated that SALL4B is also a dominant form in HpSC-HCC cell lines. It is unclear 
how SALL4 isoform expression is regulated in cancer, and future studies are required to 
explore the mechanisms of SALL4 isoform regulation. 
In the liver, SALL4 is expressed in fetal hepatic stem/progenitors but not in 
adult hepatocytes, and a mouse study demonstrated that inhibition of SALL4 in hepatic 
stem/progenitors contributes to their differentiation [33]. Interestingly, recent studies 
indicated that AFP-producing gastric cancer expresses SALL4, suggesting that SALL4 
might play a role in the hepatoid differentiation of gastric cancer [34]. Consistently, our 
data indicated a positive correlation between SALL4, AFP, and EPCAM expression in 
two independent HCC cohorts. Strikingly, SALL4 was recently shown to be expressed 
in a subset of human liver cancers with poor prognoses, while modification of SALL4 
expression resulted in the alteration of cell proliferation in vitro and tumor growth in 
vivo, consistent with our current study [35]. A recent study reported the expression of 
SALL4 in 46% of HCC cases, which is almost comparable to our present study [36]. 
Furthermore, a very recent study of two independent large cohorts demonstrated that 
SALL4 is a marker for a progenitor subclass of HCC with an aggressive phenotype [37]. 
It is still unclear how SALL4 expression is regulated and which target genes are directly 
activated by SALL4 binding. Future studies using next generation sequencing are 
required to fully understand the mechanisms of SALL4 regulation of HCC stemness. 
In this study, we demonstrated that SALL4-positive HCC cell lines have high 
HDAC activity and chemosensitivity against the HDAC inhibitors SBHA and SAHA 
compared with SALL4-negative HCC cell lines. SALL4 was recently found to directly 
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connect with the epigenetic modulator NuRD complex [22], thereby possible affecting 
the histone modification associated with stemness. The NuRD complex is a multiunit 
chromatin remodeling complex containing chromodomain-helicase-DNA-binding 
proteins and HDACs that regulate histone deacetylation [38]. Its role in cancer is still 
controversial, while its function in HCC has not yet been determined.  
Our data suggest that SALL4 plays a role in controlling HDAC activity and 
contributing to the maintenance of HCC with stem cell features. Consistently, HDAC 
inhibitors might be useful for the eradication of SALL4-positive HCC cells through 
their inhibitory effects on histone deacetylation by NuRD [39]. Encouragingly, a recent 
study demonstrated the utility of a SALL4-binding peptide to inhibit its binding to 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) through interaction 
with HDAC, thereby targeting leukemia cells [21]. Further studies are required to 
understand the relationship between SALL4, the NuRD complex, and the maintenance 
of stemness in HCC. 
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Table 1. Clinicopathological characteristics of SALL4-positive and -negative HCC 
cases used for IHC analyses 
Parameters 
SALL4-positive SALL4-negative 
P-value* (n = 43) (n = 101) 
Age (years, mean ± SE) 60.8 ± 1.8 64.6 ± 1.0 0.13 
Sex (Male/Female) 27/16 70/18 0.06 
Etiology (HBV/ HCV/ 
B+C/Other) 21/14/0/8 20/63/3/15 0.0014 
Liver cirrhosis (Yes/No) 21/22 61/40 0.27 
AFP (ng/ml, mean ± SE) 13,701 ± 9,292 175.5 ± 55.0 <0.0001 
Histological grade** 
   I-II 3 18 
 II-III 33 68 
 III-IV 7 15 0.24 
Tumor size (<3cm/>3cm) 17/26 57/44 0.071 
EpCAM (Positive/Negative) 27/16 29/72 0.0002 
CK19 (Positive/Negative) 12/31 12/89 0.027 





Figure 1 Transcription factors potentially activated in HpSC-HCC. A. Transcription 
Factor Analysis. Transcription factors regulating genes up-regulated in HpSC-HCC are 
listed with their P-values and Z-scores as calculated by MetaCore software. B. 
Interaction Network Analysis. Seven genes (ABL1, DMRT1, DNMT3B, JARID2, NFYA, 
SP1, and TCF7L2, indicated in orange) shown to be up-regulated in HpSC-HCC were 
identified as potential target genes regulated by SALL4 (indicated in red). C. SALL4 
gene expression evaluated by microarray analysis. Tumor/non-tumor (T/N) ratios of 
microarray data in HpSC-HCC (n = 60, indicated in red) and MH-HCC (n = 96, 
indicated in green). D. SALL4 gene expression evaluated by qRT-PCR. Gene 
expression of SALL4 in HpSC-HCC (n = 8, indicated in red) and MH-HCC (indicated in 
green) samples. E. Scatter plot analysis. Gene expression levels of EPCAM (upper 
panel) and AFP (lower panel) were positively correlated with those of SALL4 in 
microarray data (n = 238, T/N ratios), as shown by Spearman’s correlation coefficients. 
F. Scatter plot analysis. Gene expression levels of EPCAM (upper panel) and AFP 
(lower panel) were positively correlated with those of SALL4 in qRT-PCR data (n = 61), 
as shown by Spearman’s correlation coefficients.  
Figure 2 SALL4 expression in human primary HCCs and cell lines. A. Representative 
images of SALL4-positive (left) and -negative (right) HCC immunostaining (scale bar, 
100 µm). B. Gene expression of SALL4 in SALL4-positive (n = 13) and -negative HCCs 
(n = 14) as shown by IHC (mean ± SD). C. Double color IHC analysis of HCC stained 
with anti-SALL4 and anti-EpCAM (left panel) or anti-CK19 (right panel) antibodies 
(scale bar, 100 µm). D. Kaplan-Meier survival analysis with log-rank. Recurrence-free 
survival of SALL4-positive (n = 43) and -negative (n = 101) HCCs was analyzed. E. 
22 
SALL4 expression in EpCAM+ (Hep3B, HuH7, and HuH1) and EpCAM- (SK-Hep-1, 
HLE, and HLF) HCC cell lines evaluated by qRT-PCR. F. SALL4 expression in 
EpCAM+ and EpCAM- HCC cell lines evaluated by Western blotting. G. IHC analysis 
of SALL4 expression in subcutaneous tumors obtained from EpCAM+ (HuH7 and 
Hep3B) HCC cell lines xenografted in NOD/SCID mice. H. Spheroid formation 
capacity of sorted EpCAM+ and EpCAM- cells obtained from a primary HCC (left 
panel). Number of spheroids obtained from 2,000 sorted cells is indicated (n = 3, mean 
± SD). Gene expression of SALL4 in sorted EpCAM+ and EpCAM- cells obtained from 
a primary HCC (n = 3, mean ± SD) (right panel). 
Figure 3 Effect of SALL4 overexpression. A. Western blots of cell lysates with 
anti-SALL4 antibodies. HuH1 cells were transfected with pCMV7 or pCMV6-SALL4 
and incubated for 72 h. B. IF analysis of HuH1 cells transfected with pCMV7 or 
pCMV6-SALL4 and incubated for 72 h. C. qRT-PCR analysis of KRT19, EPCAM, 
CD44, and ALB in HuH1 cells transfected with pCMV7 or pCMV6-SALL4 and 
incubated for 48 h. D. IF analysis of HuH1 cells transfected with pCMV7 or 
pCMV6-SALL4, incubated for 72 h and stained with anti-CK19 antibodies, evaluated 
by the confocal laser scanning microscopy. E. Spheroid formation assay of HuH1 cells 
transfected with pCMV7 or pCMV6-SALL4. Number of spheroids obtained from 2,000 
cells is indicated (n = 3, mean ± SD). F. Invasion assay of HuH1 cells transfected with 
pCMV7 or pCMV6-SALL4 (n = 3, mean ± SD).  
Figure 4 Effect of SALL4 knockdown and HDAC activity. A. qRT-PCR analysis of 
SALL4 in HuH7 cells transfected with control or SALL4 sh-RNAs (n = 3, mean ± SD). 
B. Western blots of lysates obtained from HuH7 cells transfected with control or 
SALL4 sh-RNAs with anti-SALL4 antibodies. C. qRT-PCR analysis of EPCAM and 
23 
CD44 in HuH7 cells transfected with control or SALL4 sh-RNAs (n = 3, mean ± SD). 
D. Invasion assay of HuH7 cells transfected with control or SALL4 sh-RNAs (n = 3, 
mean ± SD). E. HDAC activity of nuclear extracts obtained from HuH7 cells 
transfected with control or SALL4 sh-RNAs. F. HDAC activity of nuclear extracts 
obtained from each cell line. HDAC activity was measured in duplicate and average 
amounts of deacetylated products are indicated (upper panel). Lamin B included in the 
nuclear extracts loaded for HDAC activity assays was measured by Western blotting 
(lower panel). G. Cell proliferation assay of HCC cell lines. Each cell line was treated 
with control DMSO (white bar) or 10 µM SBHA (black bar) and cultured for 72 h (n = 
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Age (yr, mean ± SE) 60.8 ± 1.8 64.6 ± 1.0 0.13
Sex (male/female) 27/16 70/18 0.06
Etiology (HBV/HCV/B + C/other) 21/14/0/8 20/63/3/15 0.0014
Liver cirrhosis (yes/no) 21/22 61/40 0.27




III-IV 7 15 0.24
Tumor size (<3 cm/>3 cm) 17/26 57/44 0.071
EpCAM (positive/negative) 27/16 29/72 0.0002
CK19 (positive/negative) 12/31 12/89 0.027
